AbbVie Inc (ABBV)vsWerewolf Therapeutics Inc (HOWL)
ABBV
AbbVie Inc
$294.90
+3.09%
HEALTHCARE · Cap: $521.11B
HOWL
Werewolf Therapeutics Inc
$1.07
+1.90%
HEALTHCARE · Cap: $47.93M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 314252% more annual revenue ($66.01B vs $21.00M). ABBV leads profitability with a 15.7% profit margin vs -164.8%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
HOWL
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.0%
Fair Value
$156.84
Current Price
$294.90
$138.06 premium
Margin of Safety
+85.7%
Fair Value
$4.68
Current Price
$1.07
$3.61 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 40.6%
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -461.1% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : HOWL
The strongest argument for HOWL centers on Operating Margin.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : HOWL
The primary concerns for HOWL are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a mature stock while HOWL is a turnaround play — different risk/reward profiles.
HOWL carries more volatility with a beta of 0.51 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (3.1B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 31/100), backed by strong 15.7% margins and 10.3% revenue growth. HOWL offers better value entry with a 85.7% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Werewolf Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?